• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Atara Biotherapeutics Inc.

    11/14/25 4:19:25 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ATRA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)


    Atara Biotherapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    046513206

    (CUSIP Number)


    Joshua Garcia
    Redmile Group, LLC, One Letterman Drive Bldg D, Ste D3-300
    San Francisco, CA, 94129
    (415) 489-9980

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    11/12/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    046513206


    1 Name of reporting person

    Redmile Group, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    751,223.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    751,223.00
    11Aggregate amount beneficially owned by each reporting person

    751,223.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    9.9 %
    14Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:
    Redmile Group, LLC's beneficial ownership of the Issuer's common stock ("Common Stock") is comprised of 441,701 shares of Common Stock owned by certain private investment vehicles managed by Redmile Group, LLC (the "Redmile Funds"), including RedCo I, L.P. ("RedCo I"), Redmile Biopharma Investments II, L.P. ("RBI II") and Redmile Strategic Long Only Trading Sub, Ltd. ("Redmile Long Only"). Subject to the Beneficial Ownership Blocker (as defined below), Redmile Group, LLC may also be deemed to beneficially own 3,412,843 shares of Common Stock issuable upon exercise of certain pre-funded warrants to purchase Common Stock (the "Warrants") held directly by the Redmile Funds. Pursuant to the terms of the Warrants, the Issuer may not effect any exercise of the Warrants, and a holder of a Warrants does not have the right to exercise the Warrants held by such holder, to the extent that after giving effect to such issuance after exercise, the holder (together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates), would beneficially own in excess of 9.99% (the "Beneficial Ownership Limitation") of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issued upon exercise of the Warrant (the "Beneficial Ownership Blocker"). The Beneficial Ownership Limitation may be changed at a holder's election upon 61 days' notice to the Issuer. The 751,223 shares of Common Stock reported as beneficially owned by Redmile Group, LLC in this Schedule 13D represent 9.99% of the outstanding shares of Common Stock (calculated in accordance with the footnote below) and includes 309,522 shares of Common Stock that could be issued upon exercise of certain of the Warrants directly held by the Redmile Funds under the Beneficial Ownership Blocker. The reported securities may be deemed beneficially owned by Redmile Group, LLC as investment manager of the Redmile Funds. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Percentage based on the sum of: (i) 7,210,235 shares of Common Stock outstanding as of November 6, 2025, as reported by the Issuer in its Form 10-Q for the quarterly period ended September 30, 2025 filed with the Securities and Exchange Commission (the "SEC") on November 11, 2025 (the "Form 10-Q"), plus (ii) 309,522 shares of Common Stock issuable upon exercise of the Warrants directly held by the Redmile Funds, which due to the Beneficial Ownership Limitation is the maximum number of shares that could be issued upon exercise of those Warrants.


    SCHEDULE 13D

    CUSIP No.
    046513206


    1 Name of reporting person

    Jeremy C. Green
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    751,223.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    751,223.00
    11Aggregate amount beneficially owned by each reporting person

    751,223.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    9.9 %
    14Type of Reporting Person (See Instructions)

    IN, HC

    Comment for Type of Reporting Person:
    Jeremy C. Green's beneficial ownership of Common Stock is comprised of 441,701 shares of Common Stock owned by the Redmile Funds, including RedCo I, RBI II and Redmile Long Only. Subject to the Beneficial Ownership Blocker, Mr. Green may also be deemed to beneficially own 3,412,843 shares of Common Stock issuable upon exercise of the Warrants held directly by the Redmile Funds. Pursuant to the terms of the Warrants, the Issuer may not effect any exercise of the Warrant, and a holder of a Warrant does not have the right to exercise the Warrant held by such holder, to the extent that the Beneficial Ownership Blocker applies. The 751,223 shares of Common Stock reported as beneficially owned by Mr. Green in this Schedule 13D represent 9.99% of the outstanding shares of Common Stock (calculated in accordance with the footnote below) and includes 309,522 shares of Common Stock that could be issued upon exercise of certain of the Warrants directly held by the Redmile Funds under the Beneficial Ownership Blocker. The reported securities may be deemed beneficially owned by Redmile Group, LLC as investment manager of the Redmile Funds. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Percentage based on the sum of: (i) 7,210,235 shares of Common Stock outstanding as of November 6, 2025, as reported by the Issuer in its Form 10-Q, plus (ii) 309,522 shares of Common Stock issuable upon exercise of the Warrants directly held by the Redmile Funds, which due to the Beneficial Ownership Limitation is the maximum number of shares that could be issued upon exercise of those Warrants.


    SCHEDULE 13D

    CUSIP No.
    046513206


    1 Name of reporting person

    RedCo I, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    347,442.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    347,442.00
    11Aggregate amount beneficially owned by each reporting person

    347,442.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.7 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    The shares of Common Stock reported as beneficially owned by RedCo I in this Schedule 13D represent the 191,226 shares of Common Stock held directly by RedCo I and the 156,216 shares of Common Stock that could be issued to RedCo I upon exercise of the Warrants directly held by RedCo I. Percentage based on the sum of: (i) 7,210,235 shares of Common Stock outstanding as of November 6, 2025, as reported by the Issuer in its Form 10-Q, plus (ii) 156,216 shares of Common Stock issuable upon exercise of the Warrants directly held by RedCo I.


    SCHEDULE 13D

    CUSIP No.
    046513206


    1 Name of reporting person

    Redmile Biopharma Investments II, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    452,153.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    452,153.00
    11Aggregate amount beneficially owned by each reporting person

    452,153.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.0 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    RBI II's beneficial ownership of Common Stock is comprised of 142,631 shares of Common Stock directly held by RBI II. Subject to the Beneficial Ownership Blocker, RBI II may also be deemed to beneficially own 2,054,155 shares of Common Stock issuable upon exercise of the Warrants directly held by RBI II. Pursuant to the terms of the Warrants, the Issuer may not effect any exercise of any Warrant, and a holder of a Warrant does not have the right to exercise any portion of the Warrant held by such holder, if the Beneficial Ownership Blocker applies. The shares of Common Stock reported as beneficially owned by RBI II in this Schedule 13D represent the shares of Common Stock held directly by RBI II and the 309,522 shares of Common Stock that could be issued to RBI II upon exercise of certain of the Warrants directly held by RBI II under the Beneficial Ownership Blocker. Percentage based on the sum of: (i) 7,210,235 shares of Common Stock outstanding as of November 6, 2025, as reported by the Issuer in its Form 10-Q, plus (ii) 309,522 shares of Common Stock issuable upon exercise of the Warrants directly held by RBI II, which due to the Beneficial Ownership Limitation is the maximum number of shares that could be issued upon exercise of those Warrants.


    SCHEDULE 13D

    CUSIP No.
    046513206


    1 Name of reporting person

    Redmile Strategic Long Only Trading Sub, Ltd.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    376,377.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    376,377.00
    11Aggregate amount beneficially owned by each reporting person

    376,377.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    5.0 %
    14Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:
    Redmile Long Only's beneficial ownership of Common Stock is comprised of 66,855 shares of Common Stock directly held by Redmile Long Only. Subject to the Beneficial Ownership Blocker, Redmile Long Only may also be deemed to beneficially own 827,581 shares of Common Stock issuable upon exercise of the Warrants directly held by Redmile Long Only. Pursuant to the terms of the Warrants, the Issuer may not effect any exercise of any Warrant, and a holder of a Warrant does not have the right to exercise any portion of the Warrant held by such holder, if the Beneficial Ownership Blocker applies. The shares of Common Stock reported as beneficially owned by Redmile Long Only in this Schedule 13D represent the shares of Common Stock held directly by Redmile Long Only and the 309,522 shares of Common Stock that could be issued to Redmile Long Only upon exercise of certain of the Warrants directly held by Redmile Long Only under the Beneficial Ownership Blocker. Percentage based on the sum of: (i) 7,210,235 shares of Common Stock outstanding as of November 6, 2025, as reported by the Issuer in its Form 10-Q, plus (ii) 309,522 shares of Common Stock issuable upon exercise of the Warrants directly held by Redmile Long Only, which due to the Beneficial Ownership Limitation is the maximum number of shares that could be issued upon exercise of those Warrants.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, par value $0.0001 per share
    (b)Name of Issuer:

    Atara Biotherapeutics, Inc.
    (c)Address of Issuer's Principal Executive Offices:

    1280 Rancho Conejo Blvd, Thousand Oaks, CALIFORNIA , 91320.
    Item 2.Identity and Background
    (a)
    This Amendment No. 1 to Schedule 13D amends and supplements the Schedule 13D filed with the SEC on May 23, 2025 (the "Prior Schedule 13D") to reflect the addition of Redmile Strategic Long Only Trading Sub, Ltd. ("Redmile Long Only"). Redmile Long Only became a reporting person solely as a result of an increase in the aggregate number of the Issuer's outstanding Common Stock, which increased the number of shares of Common Stock issuable to Redmile Long Only upon exercise of certain pre-funded warrants to purchase Common Stock under the beneficial ownership limitation. The Reporting Persons have not engaged in any transactions since the Prior Schedule 13D. Capitalized terms used but not defined in this Amendment No. 1 shall have the meanings set forth in the Prior Schedule 13D. Except as specifically amended by this Amendment No. 1, the Prior Schedule 13D is unchanged. Item 2(a) of the Prior Schedule 13D is hereby amended and restated in its entirety as follows: This Schedule 13D is being filed jointly by Redmile Group, LLC ("Redmile"), Jeremy C. Green, RedCo I, L.P. ("RedCo I"), Redmile Biopharma Investments II, L.P. ("RBI II"), and Redmile Long Only (collectively with Redmile, Mr. Green, RedCo I and RBI II, the "Reporting Persons"), pursuant to the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as separate persons and not as members of a group. See Exhibit 99.1 to this Schedule 13D for their Joint Filing Agreement.
    (b)
    Item 2(b) of the Prior Schedule 13D is hereby amended and restated in its entirety as follows: Redmile: One Letterman Drive Building D, Suite D3-300 The Presidio of San Francisco San Francisco, California 94129 Jeremy C. Green: c/o Redmile Group, LLC (NY Office) 45 W. 27th Street, Floor 11 New York, NY 10001 RedCo I: c/o Redmile Group, LLC One Letterman Drive Building D, Suite D3-300 The Presidio of San Francisco San Francisco, California 94129 RBI II: c/o Redmile Group, LLC One Letterman Drive Building D, Suite D3-300 The Presidio of San Francisco San Francisco, California 94129 Redmile Long Only: c/o Redmile Group, LLC One Letterman Drive Building D, Suite D3-300 The Presidio of San Francisco San Francisco, California 94129
    (c)
    Item 2(c) of the Prior Schedule 13D is hereby amended and restated in its entirety as follows: Redmile: investment manager/adviser to certain private investment vehicles Jeremy C. Green: managing member of Redmile RedCo I: private investment fund RBI II: private investment fund Redmile Long Only: private investment fund
    (f)
    Item 2(f) of the Prior Schedule 13D is hereby amended and restated in its entirety as follows: Redmile: Delaware Jeremy C. Green: United Kingdom RedCo I: Delaware RBI II: Delaware Redmile Long Only: Cayman Islands
    Item 5.Interest in Securities of the Issuer
    (a)
    Item 5(a) of the Prior Schedule 13D is hereby amended and restated in its entirety as follows: The aggregate amount of shares of Common Stock that may be deemed beneficially owned by the Reporting Persons is comprised of (i) 441,701 shares of Common Stock held by the Redmile Funds, including the 191,226 shares of Common Stock directly held by RedCo I, the 142,631 shares of Common Stock directly held by RBI II and the 66,855 shares of Common Stock directly held by Redmile Long Only, and (ii) in each case subject to the Beneficial Ownership Blocker, 3,412,843 shares of Common Stock issuable upon exercise of certain pre-funded warrants to purchase Common Stock (the "Warrants"), including the 156,216 shares of Common Stock issuable upon exercise of the Warrants directly held by RedCo I, the 2,054,155 shares of Common Stock issuable upon exercise of the Warrants directly held by RBI II, and the 827,581 shares of Common Stock issuable upon exercise of the Warrants directly held by Redmile Long Only. Redmile is the investment manager to the Redmile Funds and, in such capacity, exercises voting and investment power over all of the shares held by the Redmile Funds and may be deemed to be the beneficial owner of these shares. Jeremy C. Green serves as the managing member of Redmile and also may be deemed to be the beneficial owner of these shares. Redmile and Mr. Green each disclaims beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Pursuant to the terms of the Warrants, the Issuer may not effect any exercise of the Warrants, and a holder of a Warrants does not have the right to exercise the Warrants held by such holder, to the extent that after giving effect to such issuance after exercise, the holder (together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates), would beneficially own in excess of 9.99% (the "Beneficial Ownership Limitation") of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issued upon exercise of the Warrant (the "Beneficial Ownership Blocker"). The Beneficial Ownership Limitation may be changed at a holder's election upon 61 days' notice to the Issuer. The 751,223 shares of Common Stock reported as beneficially owned by Redmile and Mr. Green in this Schedule 13D represent 9.99% of the outstanding shares of Common Stock. The 347,442 shares of Common Stock reported as beneficially owned by RedCo I in this Schedule 13D represent 4.7% of the outstanding shares of Common Stock. The 452,153 shares of Common Stock reported as beneficially owned by RBI II in this Schedule 13D represent 6.0% of the outstanding shares of Common Stock. The 376,377 shares of Common Stock reported as beneficially owned by Redmile Long Only in this Schedule 13D represent 5.0% of the outstanding shares of Common Stock. For purposes of this Schedule 13D, the percent of class for each Reporting Person, other than RedCo I, was calculated based on sum of: (i) 7,210,235 shares of Common Stock outstanding as of November 6, 2025, as reported by the Issuer in its Form 10-Q for the quarterly period ended September 30, 2025 filed with the SEC on November 12, 2025 (the "Form 10-Q"), plus (ii) 309,522 shares of Common Stock issuable upon exercise of the Warrants directly held by the Redmile Funds, which due to the Beneficial Ownership Limitation is the maximum number of shares that could be issued upon exercise of those Warrants. The percent of class for RedCo I was calculated based on sum of: (i) 7,210,235 shares of Common Stock outstanding as of November 6, 2025, as reported by the Issuer in its Form 10-Q, plus (ii) 156,216 shares of Common Stock issuable upon exercise of the Warrants directly held by RedCo I, which due to the Beneficial Ownership Limitation is the maximum number of shares that could be issued upon exercise of those Warrants.
    (b)
    Item 5(b) of the Prior Schedule 13D is hereby amended and restated in its entirety as follows: Redmile: (1) Sole Voting Power: 0 (2) Shared Voting Power: 751,223 (3) Sole Dispositive Power: 0 (4) Shared Dispositive Power: 751,223 Jeremy C. Green: (1) Sole Voting Power: 0 (2) Shared Voting Power: 751,223 (3) Sole Dispositive Power: 0 (4) Shared Dispositive Power: 751,223 RedCo I: (1) Sole Voting Power: 0 (2) Shared Voting Power: 347,442 (3) Sole Dispositive Power: 0 (4) Shared Dispositive Power: 347,442 RBI II: (1) Sole Voting Power: 0 (2) Shared Voting Power: 452,153 (3) Sole Dispositive Power: 0 (4) Shared Dispositive Power: 452,153 Redmile Long Only: (1) Sole Voting Power: 0 (2) Shared Voting Power: 376,377 (3) Sole Dispositive Power: 0 (4) Shared Dispositive Power: 376,377
    (e)
    RedCo I ceased to be a 5% beneficial owner when the Issuer reported the increase in its outstanding Common Stock in its Form 10-Q filed on November 12, 2025.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit 99.3: Joint Filing Agreement, dated as of November 14, 2025, by and among Redmile, Jeremy C. Green, RedCo I, RBI II and Redmile Long Only.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Redmile Group, LLC
     
    Signature:/s/ Jeremy C. Green
    Name/Title:Managing Member
    Date:11/14/2025
     
    Jeremy C. Green
     
    Signature:/s/ Jeremy C. Green
    Name/Title:Jeremy C. Green
    Date:11/14/2025
     
    RedCo I, L.P.
     
    Signature:/s/ Jeremy C. Green
    Name/Title:Managing Member of RedCo I (GP), LLC, general partner of RedCo I, L.P.
    Date:11/14/2025
     
    Redmile Biopharma Investments II, L.P.
     
    Signature:/s/ Jeremy C. Green
    Name/Title:Managing Member of Redmile Biopharma Investments II (GP), LLC, general partner of Redmile Biopharma Investments II, L.P.
    Date:11/14/2025
     
    Redmile Strategic Long Only Trading Sub, Ltd.
     
    Signature:/s/ Jeremy C. Green
    Name/Title:Managing Member of Redmile Group, LLC, investment manager of Redmile Strategic Long Only Trading Sub, Ltd.
    Date:11/14/2025
    Get the next $ATRA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATRA

    DatePrice TargetRatingAnalyst
    11/9/2023Outperform → In-line
    Evercore ISI
    11/9/2023Buy → Neutral
    H.C. Wainwright
    11/9/2023$31.00 → $1.00Buy → Neutral
    Mizuho
    7/20/2022$8.00 → $3.00Neutral → Sell
    Citigroup
    7/13/2022$10.00Overweight → Neutral
    JP Morgan
    7/13/2022$16.00 → $5.00Buy → Hold
    Stifel
    5/10/2022$15.00 → $8.00Buy → Neutral
    Citigroup
    1/3/2022$26.00 → $27.00Overweight
    JP Morgan
    More analyst ratings

    $ATRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress

    Tab-cel Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026 Atara has completed the transfer of substantially all tab-cel activities, including BLA sponsorship, and associated costs to Pierre Fabre Laboratories Approval of BLA would unlock a $40 Million milestone payment from Pierre Fabre Laboratories Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2025 and business updates. Tabelecleucel (tab-cel® or Ebvallo™) for Pos

    11/12/25 9:00:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

    Tabelecleucel BLA currently under U.S. Food and Drug Administration (FDA) Priority Review as potentially the first approved therapy in the U.S. for EBV+ PTLD with a Prescription Drug User Fee Act (PDUFA) target action date of January 10, 2026 First allogeneic T-Cell therapy BLA offers hope to EBV+ PTLD patients who have limited treatment options and lifespan measured in only a few weeks to months following failure of initial treatment EBV+ PTLD is an ultra-rare, acute, and potentially deadly blood malignancy that occurs after hematopoietic cell transplant (HCT) or solid organ transplant (SOT) when T-cell activity is impaired by immunosuppression Pierre Fabre Laboratories and its subsidiaries

    11/3/25 9:00:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics Announces Changes to Its Board of Directors

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Greg Ciongoli will assume the role of Chair of the Board of Directors. Greg Ciongoli is the founder and managing partner of Adiumentum Capital Management. He has served as a Director at Atara since 2024. In addition to his role as Chair of the Board, Greg will also serve as a member of the Nominating and Corporate Governance Committee. "I am honored to serve as Board Chair of Atara. I deeply appreciate how tirelessly Atara's team has

    9/3/25 6:00:00 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Nguyen Anhco sold $38,437 worth of shares (2,915 units at $13.19), decreasing direct ownership by 4% to 64,974 units (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    11/19/25 4:55:17 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Accounting Officer Grant-Huerta Yanina sold $23,788 worth of shares (1,804 units at $13.19), decreasing direct ownership by 5% to 33,454 units (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    11/19/25 4:55:00 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Nguyen Anhco sold $34,360 worth of shares (2,958 units at $11.62), decreasing direct ownership by 4% to 67,889 units (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    8/20/25 4:11:40 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Atara Biotherapeutics Inc.

    SCHEDULE 13D/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

    11/14/25 4:19:25 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Atara Biotherapeutics Inc.

    SCHEDULE 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

    11/14/25 4:05:29 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Atara Biotherapeutics Inc.

    10-Q - Atara Biotherapeutics, Inc. (0001604464) (Filer)

    11/12/25 9:10:51 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Atara Biotherapeutics downgraded by Evercore ISI

    Evercore ISI downgraded Atara Biotherapeutics from Outperform to In-line

    11/9/23 9:00:28 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Atara Biotherapeutics from Buy to Neutral

    11/9/23 7:32:43 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics downgraded by Mizuho with a new price target

    Mizuho downgraded Atara Biotherapeutics from Buy to Neutral and set a new price target of $1.00 from $31.00 previously

    11/9/23 6:45:52 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Panacea Innovation Ltd bought $670,422 worth of shares (55,000 units at $12.19) (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    8/19/25 8:15:04 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Panacea Innovation Ltd bought $186,372 worth of shares (19,335 units at $9.64) (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    7/21/25 9:00:05 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gallagher Carol Giltner bought $68,214 worth of shares (270,000 units at $0.25), increasing direct ownership by 143% to 459,418 units (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    11/15/23 5:07:08 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    Leadership Updates

    Live Leadership Updates

    View All

    CDR-Life Appoints Pascal Touchon to the Board of Directors to Support Continued Growth and Advancement of Next Generation T Cell Engager Platform

    Experienced, strategic biopharma leader with 40 years of global biopharma experience CDR-Life today announced the appointment of Pascal Touchon, DVM, MBA, to its Board of Directors. Dr. Touchon brings 40 years of international experience in the biopharmaceutical industry, with extensive expertise in oncology and strategic leadership that will further strengthen CDR-Life as it advances its innovative M-gager® platform and pipeline of T cell engager (TCE) therapeutics. "We are delighted to welcome Pascal to our Board of Directors," said Dominik Escher, Ph.D., Chairman of CDR-Life's Board of Directors. "Pascal's remarkable track record in developing and commercializing transformative thera

    5/28/25 8:00:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced the appointment of James Huang and Nachi Subramanian to its Board of Directors, effective following the completion the Company's previously announced $16 million offering that was announced on May 15, 2025. The offering closed on May 16, 2025. Mr. Huang has over 37 years of biotech experience and is the Founder and Managing Partner of Panacea Venture. Prior to Panacea Venture, Mr. Huang was a Managing Partner at Kleiner Perkins (KPCB) China where h

    5/16/25 8:50:00 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer

    Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022. A gifted physician-scientist and leading oncologist, Dr. Baynes is among the most experienced – and most successful – clinical development leaders in the biopharmaceutical industry. Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice President and Chief Medical Officer in J

    3/23/22 7:30:00 AM ET
    $ATRA
    $NTRA
    $TVTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Biotechnology: Pharmaceutical Preparations

    $ATRA
    Financials

    Live finance-specific insights

    View All

    Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2024 financial results after market close on Tuesday, Nov 12, 2024. About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the w

    11/5/24 4:01:00 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results

    Pierre Fabre Laboratories to License Commercialization Rights to Tab-cel®, including Regulatory, Manufacturing and Development Activities, in the United States and All Remaining Markets Atara to Receive Additional Payments of up to USD 640 Million, Significant Double-digit Tiered Royalties as a Percentage of Net Sales, and Funding of Tab-cel Global Development Costs Tab-cel Global Partnership and Associated Strategic Restructuring Extends Atara Cash Runway into Q3 2025 ATA188 Phase 2 EMBOLD Study Primary Analysis and Communication on Track for Early November Atara to Host Conference Call and Webcast today at 6:00 a.m. PDT / 9:00 a.m. EDT Atara Biotherapeutics, Inc. (NASDAQ:ATRA),

    11/1/23 8:30:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2023 financial results after market close on Tuesday, August 8, 2023. About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions, including multiple sclerosis, that can be rapidly delivered to patients within days. With cutting-edge science and differentiated approach, At

    8/1/23 4:01:00 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

    SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

    11/14/24 6:10:20 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

    SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

    11/14/24 4:17:31 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

    SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

    11/12/24 1:29:52 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care